• Je něco špatně v tomto záznamu ?

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC

Ľ. Křížová, M. Šafaříková, M. Kalousová, L. Pfeiferová, AA. Kuběna, M. Vočka, J. Ulrych, V. Franková, L. Petruželka, T. Zima, D. Feltl

. 2022 ; 17 (9) : e0275121. [pub] 20220926

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024352

Immunotherapy has dramatically influenced and changed therapeutical approach in non-small cell lung cancer (NSCLC) in recent five years. Even though we can reach long-term response to this treatment in approximately 20% of patients with NSCLC, we are still not able to identify this cohort of patients based on predictive biomarkers. In our study we have focused on tumor mutation burden (TMB), one of the potential biomarkers which could predict effectiveness of check-point inhibitors, but has several limitations, especially in multiple approaches to TMB quantification and ununiform threshold. We determined the value of TMB in tumor tissue (tTMB) and blood (bTMB) in 20 patients with early stage NSCLC using original custom gene panel LMB_TMB1. We evaluated various possibilities of TMB calculation and concluded that TMB should be counted from both somatic non-synonymous and synonymous mutations. Considering various factors, we established cut-offs of tTMB in/excluding HLA genes as ≥22 mut/Mb and 12 mut/Mb respectively, and cut-offs of bTMB were defined as ≥21 mut/Mb and ≥5 mut/Mb, respectively. We also observed trend in correlation of somatic mutations in HLA genes with overall survival of patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024352
003      
CZ-PrNML
005      
20240305134759.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0275121 $2 doi
035    __
$a (PubMed)36155654
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Křížová, Ľudmila $u Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000272027363
245    10
$a New methodology of TMB assessment from tissue and liquid biopsy in NSCLC / $c Ľ. Křížová, M. Šafaříková, M. Kalousová, L. Pfeiferová, AA. Kuběna, M. Vočka, J. Ulrych, V. Franková, L. Petruželka, T. Zima, D. Feltl
520    9_
$a Immunotherapy has dramatically influenced and changed therapeutical approach in non-small cell lung cancer (NSCLC) in recent five years. Even though we can reach long-term response to this treatment in approximately 20% of patients with NSCLC, we are still not able to identify this cohort of patients based on predictive biomarkers. In our study we have focused on tumor mutation burden (TMB), one of the potential biomarkers which could predict effectiveness of check-point inhibitors, but has several limitations, especially in multiple approaches to TMB quantification and ununiform threshold. We determined the value of TMB in tumor tissue (tTMB) and blood (bTMB) in 20 patients with early stage NSCLC using original custom gene panel LMB_TMB1. We evaluated various possibilities of TMB calculation and concluded that TMB should be counted from both somatic non-synonymous and synonymous mutations. Considering various factors, we established cut-offs of tTMB in/excluding HLA genes as ≥22 mut/Mb and 12 mut/Mb respectively, and cut-offs of bTMB were defined as ≥21 mut/Mb and ≥5 mut/Mb, respectively. We also observed trend in correlation of somatic mutations in HLA genes with overall survival of patients.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a nemalobuněčný karcinom plic $x patologie $7 D002289
650    _2
$a lidé $7 D006801
650    _2
$a tekutá biopsie $7 D000073890
650    12
$a nádory plic $x patologie $7 D008175
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Šafaříková, Markéta $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kalousová, Marta $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pfeiferová, Lucie $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0314741
700    1_
$a Kuběna, Aleš Antonín $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vočka, Michal $u Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Ulrych, Jan $u First Department of Surgery, Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Franková, Věra $u Department of Paediatrics and Inherited Metabolic Disorders, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Petruželka, Luboš $u Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zima, Tomáš $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Feltl, David $u Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 17, č. 9 (2022), s. e0275121
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36155654 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240305134756 $b ABA008
999    __
$a ok $b bmc $g 1854206 $s 1175642
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 17 $c 9 $d e0275121 $e 20220926 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace